LOINC
Version 2.67

49598-6Natalizumab Ab [Presence] in Serum by ImmunoassayActive

Part Descriptions

LP64671-8   Natalizumab
Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn's disease. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, Wikipedia

LP64672-6   Natalizumab Ab
Drug therapy for MS - loses effectiveness when patients develop antibodies to the drug. Detecting the antibodies early allows healthcare providers the opportunity to prescribe alternative therapy and avoid the cost associated with failed therapy. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Regenstrief Institute, Wikipedia

Fully-Specified Name

Component
Natalizumab Ab
Property
PrThr
Time
Pt
System
Ser
Scale
Ord
Method
IA

Additional Names

Short Name
Natalizumab Ab Ser Ql IA
Display Name
Natalizumab Ab IA Ql (S)

Basic Attributes

Class
SERO
Type
Laboratory
First Released
Version 2.22
Last Updated
Version 2.56
Change Reason
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation
Both

Example Answer List LL360-9

Source: Regenstrief Institute

Answer Code Score Answer ID
Positive Copyright http://snomed.info/sct ID:10828004 Positive (qualifier value) LA6576-8
Negative Copyright http://snomed.info/sct ID:260385009 Negative (qualifier value) LA6577-6

Member of these Groups

LG19693-7 Natalizumab Ab|PrThr|Pt|ANYBldSerPl

Language Variants Get Info

zh-CNChinese (CHINA)
那他珠单抗 抗体:存在情况或阈值:时间点:血清:序数型:免疫测定法
nl-NLDutch (NETHERLANDS)
natalizumab As:aanwezigheid:moment:serum:ordinaal:immunoassay
et-EEEstonian (ESTONIA)
Natalisumaab antikehad:PrThr:Pt:S:Ord:IA
fr-BEFrench (BELGIUM)
Natalizumab Ac:PrThr:Temps ponctuel:Sérum:Ordinal:IA
fr-CAFrench (CANADA)
Natalizumab , Ac:Présence-Seuil:Temps ponctuel:Sérum:Ordinal:IA
fr-FRFrench (FRANCE)
Natalizumab anticorps:Présence/Seuil:Ponctuel:Sérum:Qualitatif:Immunoanalyse
it-ITItalian (ITALY)
Natalizumab , Ab:PrThr:Pt:Siero:Ord:IA
pt-BRPortuguese (BRAZIL)
NatalizumAc Ac:ACnc:Pt:Soro:Ord:Imunoensaio
ru-RURussian (RUSSIAN FEDERATION)
Натализумаб Ат:PrThr:ТчкВрм:Сыв:Пор:IA
es-ESSpanish (SPAIN)
Natilizumab Anticuerpos:PrThr:Punto temporal:Suero:Ord:IA
tr-TRTurkish (TURKEY)
Natalizumab Ab:MevcEşik:Zmlı:Ser:Srl:İA

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=49598-6